Definium Therapeutics, Inc.
DFTXNasdaq
$44.29
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↑ +416.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.8B
Enterprise Value
$4.5B
P/E
—
P/S
—
P/B
17.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$237.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-85.2%
ROIC
—
Debt / Equity
0.1
Net Cash
$332.6M
Return 1Y
+398.8%
Company profile
Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.
- CEO
- Robert Barrow
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- New York
- Website
- mindmed.co
Management & directors
- Barrow RobertChief Executive Officer
- Karlin DanChief Medical Officer
- Roberts BrandiChief Financial Officer
- Sullivan MarkChief Legal Officer
- Wiley Matthew T.Chief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
DFTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.71↑ +102.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.0M | -$93.9M | -$66.3M | -$93.9M | -$103.9M | -$166.3M |
| Net income | -$33.9M | -$93.0M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| Diluted EPS | — | -$3.40 | -$1.84 | -$2.44 | -$1.54 | -$2.06 |
| Operating cash flow | -$23.6M | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$131.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.5M | -$24.8M | -$32.5M | -$32.2M | -$40.9M | -$45.7M | -$47.6M | -$59.2M |
| Net income | -$5.9M | -$13.7M | -$34.7M | -$23.3M | -$42.7M | -$67.3M | -$50.4M | -$77.1M |
| Diluted EPS | -$0.26 | -$0.27 | $0.13 | -$0.35 | -$0.50 | -$0.78 | -$0.43 | -$0.71 |
| Operating cash flow | -$20.0M | -$17.2M | -$25.4M | -$29.4M | -$29.6M | -$29.6M | -$43.0M | -$42.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 14, 2026
- 6d agoThe Race to Commercialize the World’s Most Powerful Psychedelicfinance.yahoo.com
- 6d agoWall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Betfinance.yahoo.com
- 6d agoNew Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | Barrow Robert· Chief Executive Officer | Sale | 29,208 | $45.03 | $1.3M | filing |
| 2026-06-25 | Sullivan Mark· Chief Legal Officer | Sale | 13,008 | $45.03 | $585,750.24 | filing |
| 2026-06-25 | Karlin Dan· Chief Medical Officer | Sale | 10,035 | $45.03 | $451,876.05 | filing |
| 2026-06-25 | Roberts Brandi· Chief Financial Officer | Sale | 3,013 | $45.03 | $135,675.39 | filing |
| 2026-06-25 | Wiley Matthew T.· Chief Commercial Officer | Sale | 2,867 | $45.03 | $129,101.01 | filing |
| 2026-06-22 | Karlin Dan· Chief Medical Officer | Award | 100,000 | $0.00 | $0.00 | filing |
| 2026-06-22 | Wiley Matthew T.· Chief Commercial Officer | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-06-22 | Barrow Robert· Chief Executive Officer | Award | 375,000 | $0.00 | $0.00 | filing |
| 2026-06-22 | Sullivan Mark· Chief Legal Officer | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-06-22 | Roberts Brandi· Chief Financial Officer | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | Krebs Andreas | Award | 4,666 | $0.00 | $0.00 | filing |
| 2026-06-11 | CRYSTAL ROGER | Award | 4,666 | $0.00 | $0.00 | filing |
| 2026-06-11 | GRYSKA DAVID W | Award | 4,666 | $0.00 | $0.00 | filing |
| 2026-06-11 | Vallone Carol A | Award | 4,666 | $0.00 | $0.00 | filing |
| 2026-06-11 | Adsett Roger | Award | 3,555 | $0.00 | $0.00 | filing |
| 2026-06-11 | Bruhn Suzanne Louise | Award | 4,666 | $0.00 | $0.00 | filing |
| 2026-03-25 | Barrow Robert· Chief Executive Officer | Sale | 24,431 | $18.47 | $451,240.57 | filing |
| 2026-03-25 | Sullivan Mark· Chief Legal Officer | Sale | 10,702 | $18.47 | $197,665.94 | filing |
| 2026-03-25 | Karlin Dan· Chief Medical Officer | Sale | 8,018 | $18.47 | $148,092.46 | filing |
| 2026-02-03 | Karlin Dan· Chief Medical Officer | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Barrow Robert· Chief Executive Officer | Award | 320,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Sullivan Mark· Chief Legal Officer | Award | 125,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Wiley Matthew T.· Chief Commercial Officer | Award | 115,000 | $0.00 | $0.00 | filing |
| 2026-02-03 | Roberts Brandi· Chief Financial Officer | Award | 150,000 | $0.00 | $0.00 | filing |
| 2025-12-26 | Barrow Robert· Chief Executive Officer | Sale | 25,791 | $13.15 | $339,071.70 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.